Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.21
+0.05004.31%
Post-market: 1.210.00000.00%19:46 EDT
Volume:186.59K
Turnover:216.88K
Market Cap:19.14M
PE:-1.53
High:1.22
Open:1.15
Low:1.11
Close:1.16
52wk High:1.84
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:1.34
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7895
EPS(LYR):-0.7811
ROE:-157.09%
ROA:-25.31%
PB:5.41
PE(LYR):-1.55

Loading ...

Allarity Therapeutics Wins Japan Patent for Stenoparib DRP Companion Diagnostic

Reuters
·
Sep 16

Allarity Therapeutics - Japan Patent Office Grants Patent for Stenoparib Drp Companion Diagnostic

THOMSON REUTERS
·
Sep 15

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

GlobeNewswire
·
Sep 15

Allarity Therapeutics - Proposed IPO Base Offering Size $100 Mln, or $115 Mln with Full Over-Allotment

THOMSON REUTERS
·
Sep 11

Allarity Therapeutics - Allarity Acquisition Corp. Files Registration Statement for Proposed IPO

THOMSON REUTERS
·
Sep 11

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

THOMSON REUTERS
·
Sep 11

Allarity Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 15

Allarity Therapeutics Q2 Loss Narrows as Expenses Fall

Reuters
·
Aug 14

Allarity Therapeutics Q2 Net Loss Per Share $0.21

THOMSON REUTERS
·
Aug 14

Allarity Therapeutics Q2 Operating Expenses USD 2.671 Million

THOMSON REUTERS
·
Aug 14

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

GlobeNewswire
·
Aug 14

Allarity Therapeutics Inc Expected to Post a Loss of 25 Cents a Share - Earnings Preview

Reuters
·
Aug 13

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

GlobeNewswire
·
Jul 07

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib Drp® Companion Diagnostic

Reuters
·
Jul 06

Allarity Therapeutics - Has Patent Protection for Stenoparib Drp in Europe and Australia into 2039

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics - Granted Patent Term Extends into April 2042

THOMSON REUTERS
·
Jun 30

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

GlobeNewswire
·
Jun 30

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO gynecological cancers congress

Reuters
·
Jun 22

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

TIPRANKS
·
Jun 18

Allarity Therapeutics to present Phase 2 stenoparib ovarian cancer trial design at ESMO Gynaecological Cancers Congress 2026

Reuters
·
Jun 18